MAP2K7 and metastatic melanoma: The results of a study evaluating the combination of dabrafenib plus trametinib, a MEK inhibitor, in patients who have unresectable or metastatic melanoma with a BRAFV600E or V600K mutation, demonstrated the long-term benefit in approximately one third of the patients [152].